An Observational Study to Evaluate Tolerability of Canagliflozin and Sulphonylurea in Type 2 Diabetes Patients During Ramadan

Diabetes Mellitus, Type 2 Clinical Trial

— CRATOS  

Official title:

Observational, Prospective, Parallel Cohort Study to Evaluate Tolerability of Canagliflozin and Sulphonylurea on a Background Therapy of Metformin With or Without a DPP-4 Inhibitor During Ramadan Fasting in Patients With Type 2 Diabetes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02737657
• Other study ID #: CR108100
• Secondary ID: 28431754DIA4016
• Status: Completed
• Phase: Phase 4
• First received: March 23, 2016
• Last updated: November 14, 2016
• Start date: April 2016
• Est. completion date: September 2016

Study information

• Verified date: November 2016
• Source: Janssen-Cilag International NV
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Arab Emirates: Medical Research Committee - Dubai Health Authority
• Study type: Observational

Clinical Trial Summary

The primary purpose of this study is to describe the tolerability of canagliflozin and any sulphonylurea (each administered with metformin with or without a DPP-4 inhibitor), in terms of the percentage of patients with at least one episode of hypoglycaemia, in patients with T2DM who fast during Ramadan.

Description:

This is non-randomized, parallel-cohort, prospective, multicenter (when more than one hospital works on a medical research study), observational study to describe the treatment of T2DM with canagliflozin during the Holy Month of Ramadan. Observed participants will be participants with T2DM (at the time of enrollment) who are being treated with either canagliflozin or any sulphonylurea, each administered on a background therapy of metformin with or without a DPP-4 inhibitor within clinical practice, and who intend to fast during the Ramadan period. On enrollment, patients will enter one of two parallel treatment cohorts based on their ongoing T2DM therapy: canagliflozin and metformin with or without a DPP-4 inhibitor will be the treatment of interest, while any sulphonylurea and metformin with or without a DPP-4 inhibitor will serve as the reference standard treatment. Safety will be monitored throughout the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 379
• Est. completion date: September 2016
• Est. primary completion date: September 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Participants who has a confirmed diagnosis of type 2 diabetes for more than 12 months before enrollment

• Participants who has been treated with canagliflozin or any sulphonylurea, each on a background therapy of metformin with or without a dipeptidyl peptidase 4 (DPP-4) inhibitor, for >12 weeks before enrollment

• Participants Intends to fast during Ramadan in 2016

• Participants Will be able to continue on the products under study (i.e., canagliflozin or any sulphonylurea, each with metformin with or without a DPP-4 inhibitor) through the Ramadan period, as judged by the participating physician

• Participants who has a glycated hemoglobin (HbA1c) measurement less than and equal to (<=) 8.5% within 8 weeks before the start of Ramadan.

Exclusion Criteria:

• Participant is being treated with insulin and/or any type 2 diabetes mellitus (T2DM) therapy other than canagliflozin, any sulphonylurea, and metformin with or without a DPP 4 inhibitor, or has changed their T2DM therapy within 12 weeks before enrollment (dose changes of canagliflozin, a sulphonylurea, metformin, and a DPP 4 inhibitor where applicable are accepted)

• Participant is currently being treated with loop diuretics

• Participants who has a history of severe hypoglycaemia events within the 6 months prior to enrollment (defined as a hypoglycaemia event for which the patient required assistance from another person, or which resulted in seizure or loss of consciousness).

• Participants who has heart failure (NYHA 3-4) or advanced cardiovascular disease.

• Participants who has an estimated glomerular filtration rate (eGFR) less than (<) 60 milliliter/minute (mL/min)/1.73 m^2.

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Janssen-Cilag International NV

Countries where clinical trial is conducted

Kuwait,  Lebanon,  United Arab Emirates, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With at Least one Episode of Hypoglycaemia	Hypoglycaemia events are defined by symptoms (e.g., dizziness, visual blurring, palpitations, nausea, sweating, confusion, tremor or intense hunger) reported by the patient in the patient diary, with confirmation by a physician where applicable; Episode may be documented via a self-monitored blood glucose measurement <70 milligram/deciliter (mg/dl).	during the Ramadan period (up to 1 month)	No
Secondary	Number of Participants With Volume Depletion Events		during the Ramadan period (up to 1 month)	No
Secondary	Treatment Adherence Based on the Percentage of Prescribed Doses of Canagliflozin or Sulphonylurea Taken by Participants		during the Ramadan period (up to 1 month)	No
Secondary	Time to the First Hypoglycaemia Event		during the Ramadan period (up to 1 month)	No
Secondary	Relationship of Hypoglycaemia Events With Clinical Parameters	Precipitating factors, symptoms and blood glucose concentration during hypoglycaemia episode will be described.	during the Ramadan period (up to 1 month)	No
Secondary	Relationship of Hypoglycaemia Events With Used Treatment	Causal relationship of hypoglycaemia event to treatment will be evaluated.	during the Ramadan period (up to 1 month)	No
Secondary	Relationship of Hypoglycaemia Events With Treatment Adherence	Treatment adherence will be based on the percentage of prescribed doses of canagliflozin or sulphonylurea that are missed during the Ramadan period, as reported in the patient diary. Any changes in study medication (i.e. missed or delayed dosing) due to hypoglycaemia events will be captured.	during the Ramadan period (up to 1 month)	No
Secondary	Relationship of Hypoglycaemia Events With Number of Fasting Days	Number of days when fasting was broken due to hypoglycaemia or hypoglycaemia prevention will be captured.	during the Ramadan period (up to 1 month)	No
Secondary	Relationship of Volume Depletion Events With Clinical Parameters	Precipitating factors, symptoms and blood glucose concentration during volume depletion related adverse events will be described.	during the Ramadan period (up to 1 month)	No
Secondary	Relationship of Volume Depletion Events With Used Treatment	Causal relationship of volume depletion related adverse event to treatment will be evaluated.	during the Ramadan period (up to 1 month)	No
Secondary	Relationship of Volume Depletion Events With Treatment Adherence	Treatment adherence will be based on the percentage of prescribed doses of canagliflozin or sulphonylurea that are missed during the Ramadan period, as reported in the patient diary. Any changes in study medication (i.e. missed or delayed dosing) due to Volume depletion related adverse events will be captured.	during the Ramadan period (up to 1 month)	No
Secondary	Relationship of Volume Depletion Events With Number of Fasting Days	Number of days when fasting was broken due to the volume depletion related adverse event will be reported.	during the Ramadan period (up to 1 month)	No

External Links

•   To learn how to participate in this trial please click here.